Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The 5q- syndrome.

A A N Giagounidis1, U Germing, J S Wainscoat

  • 1St. Johannes Hospital, Medizinische Klinik II, Duisburg, Germany. gia@krebs-duisburg.de

Hematology (Amsterdam, Netherlands)
|December 29, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification.

Leukemia·2024
Same author

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2018
Same author

Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.

Leukemia research·2017
Same author

Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.

Leukemia·2016
Same author

Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.

Leukemia·2016
Same author

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.

Leukemia·2015
Same journal

Raloxifene inhibits the proliferation of pediatric acute myeloid leukemia by targeting the ANP32B gene and regulating C-MYC expression.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Characterization of a novel α-thalassemia deletion (Dongxing deletion; --<sup>DX</sup>) by CNV-seq in a Chinese female with Hb H disease: a case report.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Sirolimus-based treatment regimens for antinuclear antibody (ANA)-positive immune thrombocytopenia: a retrospective single-center cohort study.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Relationship between major depressive disorder and venous thromboembolism: a five-ancestry genetic analysis.

Hematology (Amsterdam, Netherlands)·2026
See all related articles

The 5q- syndrome, a myelodysplastic syndrome, is characterized by a specific chromosome 5 deletion. This blood disorder typically has a good prognosis and low risk of leukemia transformation.

Area of Science:

  • Hematology
  • Cytogenetics
  • Molecular Biology

Background:

  • 5q- syndrome is a distinct myelodysplastic syndrome defined by a specific deletion on chromosome 5.
  • The molecular basis involves the loss of tumor suppressor genes within the deleted region.
  • This deletion occurs in early hematopoietic stem cells.

Purpose of the Study:

  • To analyze the clinical, cytogenetic, and prognostic features of 5q- syndrome.
  • To evaluate the survival and transformation rates in patients with 5q- syndrome.
  • To identify potential therapeutic targets for 5q- syndrome.

Main Methods:

  • Analysis of data from 60 patients with 5q- syndrome followed for up to 28 years.
  • Review of laboratory, morphological, cytogenetic, and molecular findings.

Related Experiment Videos

  • Assessment of overall survival and acute myeloid leukemia (AML) transformation rates.

    • Main Results:

    • Median age at diagnosis was 66.8 years, with a female predominance (1:1.5 male to female ratio).
    • Common cytogenetic deletions include del(5)(q13q33), del(5)(q13q31), and del(5)(q22q33).
    • Median overall survival was 107 months, with a low probability of AML transformation; increased blasts or additional anomalies reduced survival.

    Conclusions:

    • 5q- syndrome generally has a good prognosis with a low risk of AML transformation.
    • Therapeutic strategies targeting the underlying molecular mechanisms, such as CC5013, show promise.